KMT2D and neoplasm of esophagus: These studies would justify pharmacological targeting of oncogenic pathways altered by KMT2D deficiency (KMT2D truncation or loss) for the treatment of non-small cell lung tumors and esophageal tumors bearing KMT2D mutations.